Literature DB >> 1575152

New insights and approaches to reduce end-organ damage in the treatment of hypertension: subsets of hypertension approach.

M C Houston1.   

Abstract

Antihypertensive therapy should be directed toward reduction of all end-organ damage including congestive heart failure, left ventricular hypertrophy, coronary heart disease, myocardial infarction, cerebrovascular accident, and chronic renal failure. The Subsets of hypertension approach is based on pathophysiology, hemodynamics, risk factor reduction for end-organ damage, concomitant diseases and problems, demographics, adverse effects on quality of life, compliance, and total health care costs. This approach provides a more individualized and logical treatment of the hypertensive syndrome and addresses the metabolic and structural abnormalities that are present.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1575152     DOI: 10.1016/0002-8703(92)91042-y

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

Review 1.  [Cardiovascular end organ impairment due to hypertension].

Authors:  C M Schannwell; S Steiner; M G Hennersdorf; B E Strauer
Journal:  Internist (Berl)       Date:  2005-05       Impact factor: 0.743

Review 2.  [Hypertension and cardiac failure].

Authors:  C M Schannwell; M G Hennersdorf; B E Strauer
Journal:  Internist (Berl)       Date:  2007-09       Impact factor: 0.743

3.  Sympathoadrenergic overactivity and lipid metabolism.

Authors:  A Grynberg; D Ziegler; H Rupp
Journal:  Cardiovasc Drugs Ther       Date:  1996-06       Impact factor: 3.727

Review 4.  [Atenolol/nifedipine combination: efficacy and tolerability of low dose synergistic bitherapy in the treatment of arterial hypertension].

Authors:  A Krivitzky; G Nguyen; Y Gaudouen; M Legrand; R Cohen
Journal:  Drugs       Date:  1998       Impact factor: 9.546

5.  The impact of metabolic syndrome on metabolic, pro-inflammatory and prothrombotic markers according to the presence of high blood pressure criterion.

Authors:  Juliana S Gil; Luciano F Drager; Grazia M Guerra-Riccio; Cristiano Mostarda; Maria C Irigoyen; Valeria Costa-Hong; Luiz A Bortolotto; Brent M Egan; Heno F Lopes
Journal:  Clinics (Sao Paulo)       Date:  2013-12       Impact factor: 2.365

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.